The outcome of antigen recognition by naive CD8+ cytotoxic T lymphocytes (CTLs) in the
periphery is orchestrated by CD4+ T-helper cells, and can either lead to priming or …

Modest clinical outcomes of dendritic-cell (DC) vaccine trials call for the refinement of DC
vaccine design. Although many potential antigens have been identified, development of …

CD40 is essential in enabling antigen-presenting cells to process and present antigen
effectively to T cells. We demonstrate here that when antibody against CD40 is used to treat …

Tumor antigen-specific T-cell tolerance limits the efficacy of therapeutic cancer vaccines.
Antigen-presenting cells mediate the induction of T-cell tolerance to self-antigens. We …

Adequate spontaneous activation of tumor-specific T lymphocytes in tumor-bearing hosts is
rare, despite the expression of tumor antigens that are potentially highly immunogenic. For …

Although in vivo priming of CD8+ cytotoxic T lymphocytes (CTLs) generally requires the
participation of CD4+ T-helper lymphocytes,, the nature of the 'help'provided to CTLs is …

In this report we describe a potentially powerful method for vaccinating infants against
encapsulated bacterial pathogens such as Haemophilus influenzae, Streptococcus …

The use of agonistic monoclonal antibody against CD40 has emerged as one the most
effective ways to boost immune responses against infectious agents or to fight cancer. Here …

LACK of functional expression of CD40 ligand (CD40L) on T cells results in hyper-IgM
syndrome (HIGMl), a human immunodeficiency associated with a severely impaired humoral …

Therapeutic use of agonistic anti-CD40 antibodies is a potentially powerful approach for
activation of the immune response to eradicate tumors. However, the translation of this …